Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy

NCT06414577 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancer

Interventions

DRUG: Irinotecan Liposomal combined With Nituzumab

Sponsor

XIANG YANQUN